Table 2.
Studies of Combination Chemotherapy in PCNSL
| Study | N | Median Age (Range) | Therapy | CR (%) | PFS | OS | Neurotoxicity |
|---|---|---|---|---|---|---|---|
| Ferreri et al. (IELSG20) [91] | 40 | 58(27-72) | Methotrexate | 18 | 3 years 21% | 3 years 32% | - |
| 39 | 59 (25-74) | Methotrexate-cytarabine | 46 | 3 years 38% | 3 years 46% | 3% | |
| Rubenstein et al. (CALGB 50202) [19] | 44 | 61 (12-76) | R-MT (induction)-EA (consolidation) | 66 (after R-MT) |
2 years 57% | - | none |
| Glass et al. (RTOG 0227) [93] |
53 | 57 (24-73) | R-MT (induction)-WBRT (consolidation) | 51 (after R-MT) |
2 years 63.6% (R-MT + WBRT) |
2 years 80.8% (R-MT + WBRT) |
5/45 |
| Morris et al. [79] | 52 | 60 (30-79) | R-MPV (induction)-rdWBRT (consolidation) | 60 (after R-MPV) |
2 years 77% (R-MPV + rdWBRT) |
Median 6.6 years | none |
| Omuro et al. [94] | 32 | 57 (23-67) | R-MPV (induction)-ASCT (consolidation) | 44 (after R-MPV) |
2 years 81% (R-MPV + ASCT) |
2 years 81% (R-MPV + ASCT) |
- |
| Ferreri et al.(IELSG32) [88] | 75 | 58 (50-64) | Methotrexate-cytarabine | 23 | 2 years 36% | 2 years 42% | - |
| 69 | 57 (53-63) | Methotrexate-cytarabine-rituximab | 30 | 2 years 46% | 2 years 56% | - | |
| 75 | 57 (53-62) | MATRix | 49 | 2 years 61% | 2 years 69% | - |
PCNSL, primary central nervous system lymphoma; CR, complete response; EA, etoposide and cytarabine; R-MT, methotrexate, temozolomide, and rituximab; R-MPV, rituximab, methotrexate, procarbazine, and vincristine; MATRix, methotrexate, cytarabine, rituximab and thiotepa; rd, reduced-dose; WBRT, whole-brain radiation therapy; ASCT, autologous stem cell transplantation; OS, overall survival; PFS, progression-free survival; -, not mentioned.